<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>23(4)</volume><submitter>Choi S</submitter><funding>National Research Foundation of Korea</funding><pubmed_abstract>Discovering noncanonical peptides has been a common application of proteogenomics. Recent studies suggest that certain noncanonical peptides, known as noncanonical major histocompatibility complex-I (MHC-I)-associated peptides (ncMAPs), that bind to MHC-I may make good immunotherapeutic targets. De novo peptide sequencing is a great way to find ncMAPs since it can detect peptide sequences from their tandem mass spectra without using any sequence databases. However, this strategy has not been widely applied for ncMAP identification because there is not a good way to estimate its false-positive rates. In order to completely and accurately identify immunopeptides using de novo peptide sequencing, we describe a unique pipeline called proteomics X genomics. In contrast to current pipelines, it </pubmed_abstract><journal>Molecular &amp; cellular proteomics : MCP</journal><pagination>100743</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10979277</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>pXg: Comprehensive Identification of Noncanonical MHC-I-Associated Peptides From De Novo Peptide Sequencing Using RNA-Seq Reads.</pubmed_title><pmcid>PMC10979277</pmcid><pubmed_authors>Choi S</pubmed_authors><pubmed_authors>Paek E</pubmed_authors></additional><is_claimable>false</is_claimable><name>pXg: Comprehensive Identification of Noncanonical MHC-I-Associated Peptides From De Novo Peptide Sequencing Using RNA-Seq Reads.</name><description>Discovering noncanonical peptides has been a common application of proteogenomics. Recent studies suggest that certain noncanonical peptides, known as noncanonical major histocompatibility complex-I (MHC-I)-associated peptides (ncMAPs), that bind to MHC-I may make good immunotherapeutic targets. De novo peptide sequencing is a great way to find ncMAPs since it can detect peptide sequences from their tandem mass spectra without using any sequence databases. However, this strategy has not been widely applied for ncMAP identification because there is not a good way to estimate its false-positive rates. In order to completely and accurately identify immunopeptides using de novo peptide sequencing, we describe a unique pipeline called proteomics X genomics. In contrast to current pipelines, it </description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Apr</publication><modification>2026-06-01T09:51:47.196Z</modification><creation>2025-04-04T19:11:27.923Z</creation></dates><accession>S-EPMC10979277</accession><cross_references><pubmed>38403075</pubmed><doi>10.1016/j.mcpro.2024.100743</doi></cross_references></HashMap>